Journal article

Association between Mental Disorders and Subsequent Medical Conditions

NC Momen, O Plana-Ripoll, E Agerbo, ME Benros, AD Borglum, MK Christensen, S Dalsgaard, L Degenhardt, P de Jonge, J-CPG Debost, M Fenger-Gron, JM Gunn, KM Iburg, LV Kessing, RC Kessler, TM Laursen, CCW Lim, O Mors, PB Mortensen, KL Musliner Show all

New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2020

Abstract

BACKGROUND: Persons with mental disorders are at a higher risk than the general population for the subsequent development of certain medical conditions. METHODS: We used a population-based cohort from Danish national registries that included data on more than 5.9 million persons born in Denmark from 1900 through 2015 and followed them from 2000 through 2016, for a total of 83.9 million person-years. We assessed 10 broad types of mental disorders and 9 broad categories of medical conditions (which encompassed 31 specific conditions). We used Cox regression models to calculate overall hazard ratios and time-dependent hazard ratios for pairs of mental disorders and medical conditions, after adj..

View full abstract

Grants

Awarded by John Cade Fellowship from the National Health and Medical Research Council


Awarded by Novo Nordisk Foundation


Awarded by European Union's Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant


Awarded by Aarhus University Research Foundation


Awarded by Lundbeck Foundation


Awarded by National Institutes of Health (NIH)


Awarded by European Commission


Awarded by Helsefonden


Awarded by Danish Council for Independent Research


Awarded by Independent Research Fund Denmark


Awarded by NIH National Institute on Drug Abuse


Funding Acknowledgements

Supported by the Danish National Research Foundation (Niels Bohr Professorship, to Dr. McGrath), by the John Cade Fellowship (grant number APP1056929, to Dr. McGrath) from the National Health and Medical Research Council, by grants from the Novo Nordisk Foundation (NNF18OC0031194, to Dr. Prior; 22018, to Dr. Dalsgaard; and to Dr. Ribe), by the European Union's Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant (agreement number 837180, to Dr. Plana-Ripoll), by a grant from the Aarhus University Research Foundation (AUFF-E-2015-FLS-8-61, to Dr. Dalsgaard), by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003, to Dr. Dalsgaard; R102-A9118, to Drs. Werge, Nordentoft, Schork, and Vilhjalmsson; R276-2017-4581 and R248-2017-2003, to Dr. Petersen; R303-2018-3551, to Dr. Musliner; R268-2016-3925 and R278-2018-1411, to Dr. Benros; and R155-2012-11280, to Dr. Vestergaard), by a grant (R01 ES026993, to Dr. Dalsgaard) from the National Institutes of Health (NIH), by a grant (Horizon 2020, grant number 667302, to Dr. Dalsgaard) from the European Commission, by a grant (19-8-0260, to Dr. Dalsgaard) from Helsefonden, by a grant (8020-00013B, to Dr. Debost) from the Danish Council for Independent Research, by a grant (7025-00078B, to Dr. Benros) from the Independent Research Fund Denmark, by a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia (to Dr. Degenhardt), and by a grant (R01DA1104470, to Dr. Degenhardt) from the NIH National Institute on Drug Abuse.